These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 19304895)
1. Interferon-lambdas: the modulators of antivirus, antitumor, and immune responses. Li M; Liu X; Zhou Y; Su SB J Leukoc Biol; 2009 Jul; 86(1):23-32. PubMed ID: 19304895 [TBL] [Abstract][Full Text] [Related]
2. Type III Interferons in Viral Infection and Antiviral Immunity. Zhou JH; Wang YN; Chang QY; Ma P; Hu Y; Cao X Cell Physiol Biochem; 2018; 51(1):173-185. PubMed ID: 30439714 [TBL] [Abstract][Full Text] [Related]
4. Novel type III interferons produce anti-tumor effects through multiple functions. Li Q; Kawamura K; Tada Y; Shimada H; Hiroshima K; Tagawa M Front Biosci (Landmark Ed); 2013 Jun; 18(3):909-18. PubMed ID: 23747856 [TBL] [Abstract][Full Text] [Related]
5. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Kotenko SV; Gallagher G; Baurin VV; Lewis-Antes A; Shen M; Shah NK; Langer JA; Sheikh F; Dickensheets H; Donnelly RP Nat Immunol; 2003 Jan; 4(1):69-77. PubMed ID: 12483210 [TBL] [Abstract][Full Text] [Related]
6. Biological activity of interleukins-28 and -29: comparison with type I interferons. Meager A; Visvalingam K; Dilger P; Bryan D; Wadhwa M Cytokine; 2005 Jul; 31(2):109-18. PubMed ID: 15899585 [TBL] [Abstract][Full Text] [Related]
7. SOCS-1 inhibits expression of the antiviral proteins 2',5'-OAS and MxA induced by the novel interferon-lambdas IL-28A and IL-29. Brand S; Zitzmann K; Dambacher J; Beigel F; Olszak T; Vlotides G; Eichhorst ST; Göke B; Diepolder H; Auernhammer CJ Biochem Biophys Res Commun; 2005 Jun; 331(2):543-8. PubMed ID: 15850793 [TBL] [Abstract][Full Text] [Related]
8. Interferon-lambda: a new addition to an old family. Donnelly RP; Kotenko SV J Interferon Cytokine Res; 2010 Aug; 30(8):555-64. PubMed ID: 20712453 [TBL] [Abstract][Full Text] [Related]
9. Induction of an antiviral state and attenuated coxsackievirus replication in type III interferon-treated primary human pancreatic islets. Lind K; Richardson SJ; Leete P; Morgan NG; Korsgren O; Flodström-Tullberg M J Virol; 2013 Jul; 87(13):7646-54. PubMed ID: 23637411 [TBL] [Abstract][Full Text] [Related]
10. [Action of type III IFNs and their roles in immune responses]. Domagalski K; Tretyn A; Pawłowska M; Szczepanek J; Halota W Postepy Hig Med Dosw (Online); 2010 Oct; 64():522-33. PubMed ID: 21109705 [TBL] [Abstract][Full Text] [Related]
11. Type III interferons (IFNs): Emerging Master Regulators of Immunity. Galani IE; Koltsida O; Andreakos E Adv Exp Med Biol; 2015; 850():1-15. PubMed ID: 26324342 [TBL] [Abstract][Full Text] [Related]
12. Viral infections activate types I and III interferon genes through a common mechanism. Onoguchi K; Yoneyama M; Takemura A; Akira S; Taniguchi T; Namiki H; Fujita T J Biol Chem; 2007 Mar; 282(10):7576-81. PubMed ID: 17204473 [TBL] [Abstract][Full Text] [Related]
13. Integrative genomic analyses on interferon-lambdas and their roles in cancer prediction. Yang L; Wei J; He S Int J Mol Med; 2010 Feb; 25(2):299-304. PubMed ID: 20043142 [TBL] [Abstract][Full Text] [Related]
14. Expression of type III interferons (IFNλs) and their receptor in Sjögren's syndrome. Apostolou E; Kapsogeorgou EK; Konsta OD; Giotakis I; Saridaki MI; Andreakos E; Tzioufas AG Clin Exp Immunol; 2016 Dec; 186(3):304-312. PubMed ID: 27613139 [TBL] [Abstract][Full Text] [Related]
15. Comparison of antiviral activity of lambda-interferons against HIV replication in macrophages. Wang Y; Li J; Wang X; Zhou Y; Zhang T; Ho W J Interferon Cytokine Res; 2015 Mar; 35(3):213-21. PubMed ID: 25268605 [TBL] [Abstract][Full Text] [Related]
16. IL-28, IL-29 and their class II cytokine receptor IL-28R. Sheppard P; Kindsvogel W; Xu W; Henderson K; Schlutsmeyer S; Whitmore TE; Kuestner R; Garrigues U; Birks C; Roraback J; Ostrander C; Dong D; Shin J; Presnell S; Fox B; Haldeman B; Cooper E; Taft D; Gilbert T; Grant FJ; Tackett M; Krivan W; McKnight G; Clegg C; Foster D; Klucher KM Nat Immunol; 2003 Jan; 4(1):63-8. PubMed ID: 12469119 [TBL] [Abstract][Full Text] [Related]
17. Human blood dendritic cell antigen 3 (BDCA3)(+) dendritic cells are a potent producer of interferon-λ in response to hepatitis C virus. Yoshio S; Kanto T; Kuroda S; Matsubara T; Higashitani K; Kakita N; Ishida H; Hiramatsu N; Nagano H; Sugiyama M; Murata K; Fukuhara T; Matsuura Y; Hayashi N; Mizokami M; Takehara T Hepatology; 2013 May; 57(5):1705-15. PubMed ID: 23213063 [TBL] [Abstract][Full Text] [Related]
18. Human interferon-lambda3 is a potent member of the type III interferon family. Dellgren C; Gad HH; Hamming OJ; Melchjorsen J; Hartmann R Genes Immun; 2009 Mar; 10(2):125-31. PubMed ID: 18987645 [TBL] [Abstract][Full Text] [Related]